Renn A, Adejolu M, Messiou C, Bhaludin B, Strauss DC, Thway K, Moskovic E (December 2021). “Overview of malignant soft-tissue sarcomas of the limbs”. 《Clinical Radiology》 76 (12): 940.e1–940.e16. doi:10.1016/j.crad.2021.08.011. PMID34607656. S2CID238357489.
Choi JH, Ro JY (January 2021). “The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities”. 《Advances in Anatomic Pathology》 28 (1): 44–58. doi:10.1097/PAP.0000000000000284. PMID32960834. S2CID221862064.
Kamat NV, Million L, Yao DH, Donaldson SS, Mohler DG, van de Rijn M, Avedian RS, Kapp DS, Ganjoo KN (February 2019). “The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University”. 《American Journal of Clinical Oncology》 42 (2): 166–171. doi:10.1097/COC.0000000000000496. PMID30557163. S2CID56178938.
Lee K, Song JS, Kim JE, Kim W, Song SY, Lee MH, Chung HW, Cho KJ, Lee JS, Ahn JH (July 2020). “The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions”. 《European Journal of Surgical Oncology》 46 (7): 1287–1293. doi:10.1016/j.ejso.2020.02.029. PMID32127249. S2CID212406069.
Hornick JL (January 2020). “Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?”. 《Modern Pathology》 33 (Suppl 1): 56–65. doi:10.1038/s41379-019-0388-4. PMID31653978. S2CID204886468.
Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y (January 2021). “PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I”. 《Oncology Reports》 45 (1): 379–389. doi:10.3892/or.2020.7837. PMID33155664. S2CID226270021.
Liang J, Li S, Li W, Rao W, Xu S, Meng H, Zhu F, Zhai D, Cui M, Xu D, Cai J, Zhang B (November 2021). “CMTM6, a potential immunotherapy target”. 《Journal of Cancer Research and Clinical Oncology》 148 (1): 47–56. doi:10.1007/s00432-021-03835-9. PMID34783871. S2CID244132643.
Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y (July 2021). “The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma”. 《Journal of Cancer Research and Clinical Oncology》 147 (7): 2003–2011. doi:10.1007/s00432-021-03616-4. PMID33811537. S2CID232773534.
Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TL, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MM, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TG (February 2019). “Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma”. 《International Journal of Cancer》 144 (4): 859–867. doi:10.1002/ijc.31903. PMID30267407. S2CID52883298.
Renn A, Adejolu M, Messiou C, Bhaludin B, Strauss DC, Thway K, Moskovic E (December 2021). “Overview of malignant soft-tissue sarcomas of the limbs”. 《Clinical Radiology》 76 (12): 940.e1–940.e16. doi:10.1016/j.crad.2021.08.011. PMID34607656. S2CID238357489.
Choi JH, Ro JY (January 2021). “The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities”. 《Advances in Anatomic Pathology》 28 (1): 44–58. doi:10.1097/PAP.0000000000000284. PMID32960834. S2CID221862064.
Kamat NV, Million L, Yao DH, Donaldson SS, Mohler DG, van de Rijn M, Avedian RS, Kapp DS, Ganjoo KN (February 2019). “The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University”. 《American Journal of Clinical Oncology》 42 (2): 166–171. doi:10.1097/COC.0000000000000496. PMID30557163. S2CID56178938.
Lee K, Song JS, Kim JE, Kim W, Song SY, Lee MH, Chung HW, Cho KJ, Lee JS, Ahn JH (July 2020). “The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions”. 《European Journal of Surgical Oncology》 46 (7): 1287–1293. doi:10.1016/j.ejso.2020.02.029. PMID32127249. S2CID212406069.
Hornick JL (January 2020). “Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?”. 《Modern Pathology》 33 (Suppl 1): 56–65. doi:10.1038/s41379-019-0388-4. PMID31653978. S2CID204886468.
Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y (January 2021). “PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I”. 《Oncology Reports》 45 (1): 379–389. doi:10.3892/or.2020.7837. PMID33155664. S2CID226270021.
Liang J, Li S, Li W, Rao W, Xu S, Meng H, Zhu F, Zhai D, Cui M, Xu D, Cai J, Zhang B (November 2021). “CMTM6, a potential immunotherapy target”. 《Journal of Cancer Research and Clinical Oncology》 148 (1): 47–56. doi:10.1007/s00432-021-03835-9. PMID34783871. S2CID244132643.
Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y (July 2021). “The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma”. 《Journal of Cancer Research and Clinical Oncology》 147 (7): 2003–2011. doi:10.1007/s00432-021-03616-4. PMID33811537. S2CID232773534.
Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TL, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MM, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TG (February 2019). “Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma”. 《International Journal of Cancer》 144 (4): 859–867. doi:10.1002/ijc.31903. PMID30267407. S2CID52883298.
Renn A, Adejolu M, Messiou C, Bhaludin B, Strauss DC, Thway K, Moskovic E (December 2021). “Overview of malignant soft-tissue sarcomas of the limbs”. 《Clinical Radiology》 76 (12): 940.e1–940.e16. doi:10.1016/j.crad.2021.08.011. PMID34607656. S2CID238357489.
Choi JH, Ro JY (January 2021). “The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities”. 《Advances in Anatomic Pathology》 28 (1): 44–58. doi:10.1097/PAP.0000000000000284. PMID32960834. S2CID221862064.
Kamat NV, Million L, Yao DH, Donaldson SS, Mohler DG, van de Rijn M, Avedian RS, Kapp DS, Ganjoo KN (February 2019). “The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University”. 《American Journal of Clinical Oncology》 42 (2): 166–171. doi:10.1097/COC.0000000000000496. PMID30557163. S2CID56178938.
Lee K, Song JS, Kim JE, Kim W, Song SY, Lee MH, Chung HW, Cho KJ, Lee JS, Ahn JH (July 2020). “The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions”. 《European Journal of Surgical Oncology》 46 (7): 1287–1293. doi:10.1016/j.ejso.2020.02.029. PMID32127249. S2CID212406069.
Hornick JL (January 2020). “Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?”. 《Modern Pathology》 33 (Suppl 1): 56–65. doi:10.1038/s41379-019-0388-4. PMID31653978. S2CID204886468.
Vodanovich DA, Spelman T, May D, Slavin J, Choong PF (September 2019). “Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases”. 《ANZ Journal of Surgery》 89 (9): 1045–1050. doi:10.1111/ans.15348. hdl:11343/286224. PMID31364245. S2CID198997759.
Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y (January 2021). “PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I”. 《Oncology Reports》 45 (1): 379–389. doi:10.3892/or.2020.7837. PMID33155664. S2CID226270021.
Liang J, Li S, Li W, Rao W, Xu S, Meng H, Zhu F, Zhai D, Cui M, Xu D, Cai J, Zhang B (November 2021). “CMTM6, a potential immunotherapy target”. 《Journal of Cancer Research and Clinical Oncology》 148 (1): 47–56. doi:10.1007/s00432-021-03835-9. PMID34783871. S2CID244132643.
Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y (July 2021). “The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma”. 《Journal of Cancer Research and Clinical Oncology》 147 (7): 2003–2011. doi:10.1007/s00432-021-03616-4. PMID33811537. S2CID232773534.
Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TL, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MM, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TG (February 2019). “Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma”. 《International Journal of Cancer》 144 (4): 859–867. doi:10.1002/ijc.31903. PMID30267407. S2CID52883298.
